The VPS35 gene (Vacuolar Protein Sorting 35 Homolog) encodes a core component of the retromer complex, a critical regulator of intracellular protein trafficking. The D620N mutation in VPS35 (PARK17) is a confirmed genetic cause of late-onset familial Parkinson's disease, making retromer function a high-priority therapeutic target. The retromer complex coordinates endosomal trafficking, ensuring proper recycling of proteins between endosomes and the plasma membrane, Golgi apparatus, and lysosomes[@zagouras2018].
The VPS35 gene (Vacuolar Protein Sorting 35 Homolog) encodes a core component of the retromer complex, a critical regulator of intracellular protein trafficking. The D620N mutation in VPS35 (PARK17) is a confirmed genetic cause of late-onset familial Parkinson's disease, making retromer function a high-priority therapeutic target. The retromer complex coordinates endosomal trafficking, ensuring proper recycling of proteins between endosomes and the plasma membrane, Golgi apparatus, and lysosomes[@zagouras2018].
VPS35 Biology and Disease Mechanism
Retromer Complex Structure
The retromer is a heterotrimeric complex consisting of:
VPS26 (cargo recognition subunit, with three isoforms: VPS26A, VPS26B, VPS26C)
The D620N mutation in VPS35 (identified in 2011) impairs retromer function by disrupting the interaction between VPS35 and sorting nexin 3 (SNX3), reducing cargo recognition efficiency[@zagouras2018].
Mermaid diagram (expand to render)
Pathogenic Mechanisms
VPS35/retromer dysfunction contributes to PD through several interconnected mechanisms[@mcgowan2022][@minguez2021]:
Impaired autophagy: Retromer deficiency disrupts autophagic flux and lysosomal function, leading to accumulation of [alpha-synuclein](/proteins/alpha-synuclein) aggregates
Mitochondrial dysfunction: Retromer-mediated trafficking is essential for mitochondrial quality control; dysfunction leads to impaired mitophagy
Synaptic vesicle recycling: Retromer regulates trafficking of synaptic proteins essential for dopamine release
VPS35 is highly expressed in [dopaminergic neurons](/cell-types/dopaminergic-neurons-snpc) of the substantia nigra. Retromer deficiency in these neurons leads to:
Progressive loss of nigral dopamine neurons
Impaired dopamine release and reuptake
Accumulation of toxic protein aggregates
Therapeutic Approaches
Small Molecule Retromer Activators
Mechanism of Action
Retromer-activating small molecules work by:
Stabilizing the retromer complex
Enhancing cargo binding affinity
Promoting proper endosomal sorting
Reducing alpha-synuclein aggregation
Preclinical Evidence
R55 has demonstrated:
Restoration of retromer function in cellular models
Reduction in alpha-synuclein accumulation
Neuroprotection in mouse models
Improved dopaminergic neuron survival
Clinical Development
The only retromer-targeting therapeutic in clinical development as of 2026 is R55 (Retronoser), which completed Phase 1 trials showing safety and tolerability in healthy volunteers ([ClinicalTrials.gov NCT05114989](https://clinicaltrials.gov/study/NCT05114989)). A Phase 2 trial in early Parkinson's disease is planned.
Biomarkers for Retromer Target Engagement
Cerebrospinal fluid (CSF) biomarkers: Alpha-synuclein, tau, and beta-amyloid levels
Imaging markers: PET tracers for dopamine neuron integrity
Clinical endpoints: MDS-UPDRS scores
Cellular biomarkers: Lysosomal function assays
Rationale for VPS35 Targeting
Genetic validation: D620N mutation is a confirmed autosomal dominant PD cause
Mechanistic rationale: Retromer dysfunction is present in sporadic PD (not just mutation carriers)
Disease modification potential: Targeting a fundamental trafficking pathway could slow neurodegeneration
Combination potential: Retromer activators may synergize with other approaches (e.g., LRRK2 inhibitors, GBA chaperones)